IceCure’s offerings feature a minimally invasive treatment option for tumour treatment. Credit: Poonam R Kuthe / Shutterstock.

The US Food and Drug Administration (FDA) has granted marketing authorisation for IceCure Medical’s XSense Cryoablation System with CryoProbes.

This next-generation single probe system is designed for minimally invasive tumour destruction through extreme cold application.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The XSense system is now cleared for the same indications as its predecessor, the ProSense system, covering a wide range of medical fields. These include general surgery, dermatology, thoracic surgery, neurology, ENT, oncology, gynaecology, proctology, and urology.

It is capable of treating various conditions such as fibroadenomas, liver metastases, kidney tissue, tumours, skin lesions, and warts.

The technology behind IceCure’s offerings, including both the ProSense and XSense systems, offers a minimally invasive treatment option for tumour treatment.

By using liquid nitrogen, these systems can create extensive lethal zones, effectively destroying benign and malignant lesions in organs like the kidney, breast, lung, and liver.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

IceCure CEO Eyal Shamir said: “This latest FDA regulatory clearance further validates the safety and efficacy of our platform cryoablation technology.

“The next-generation XSense system is cleared for the same indications as our flagship ProSense system and we believe it has future potential to address other indications in the US for significant indications with unmet needs.

“Through our innovation, IceCure is a global leader in liquid nitrogen-based cryoablation systems that offer a new minimally invasive treatment with benefits for patients, doctors and payors alike.”

In March 2024, IceCure obtained the Japan Patent Office’s Notice of Allowance for a patent application related to its ProSense cryoablation technology.

The ProSense cryoablation technology uses advanced cryogen flow control to maintain precise temperature.